Retatrutide Dosage and Dosing : What the Clinical Trials Actually Used
Quick answer: There is no approved retatrutide dosage, because retatrutide is not an approved drug. In the Phase 3 TRIUMPH trials, the retatrutide dosing schedule started at 2 mg once weekly and escalated every four weeks through 4 mg, 6 mg, and 9 mg to a maximum of 12 mg — reaching the top dose around week 17. Maintenance arms were set at 4 mg, 9 mg, or 12 mg. Higher doses produced more weight loss but worse tolerability, and the trade-off is not linear.
The Retatrutide Dosing Schedule Used in Phase 3
TRIUMPH-1 and TRIUMPH-4 both used stepwise titration rather than a fixed dose. Participants began low and increased at four-week intervals, which allows the gastrointestinal system to adapt before concentrations build.
| Weeks | Dose | Purpose |
|---|---|---|
| 1–4 | 2 mg | Initiation — tolerance, not weight loss |
| 5–8 | 4 mg | First maintenance arm target |
| 9–12 | 6 mg | Intermediate step |
| 13–16 | 9 mg | Second maintenance arm target |
| 17 onward | 12 mg | Highest studied maintenance dose |
Four weeks at each step. Maintenance arms stopped at 4 mg, 9 mg, or 12 mg.
Source: TRIUMPH Phase 3 trial protocols; Giblin K et al., Diabetes Obes Metab 2026. This describes what was administered under medical supervision in clinical trials. Retatrutide has no approved dosage.
Participants assigned to the 4 mg or 9 mg arms stopped escalating at their assigned target and remained there. Only the 12 mg arm climbed the full ladder.
Retatrutide was given as a once-weekly subcutaneous injection on a fixed seven-day interval throughout every trial.
Why Retatrutide Dosage Charts Online Contradict Each Other
Search for a retatrutide dosage chart and you will find at least four different schedules presented as “the trial protocol” — 2→4→8→12, 1→4→8→12, 2→4→6→9→12, and versions starting at 0.5 mg. They cannot all be right.
The confusion has a real source. Phase 2 and Phase 3 used different designs.
The Phase 2 trial published in the New England Journal of Medicine tested target doses of 1, 4, 8, and 12 mg, and it used more than one escalation path to reach the same target. Some participants reached 4 mg starting from 2 mg; others started at 4 mg directly. The same applied at 8 mg. This is why Phase 2 results are often reported as “4 mg (combined)” and “8 mg (combined)” — they pool two different routes to the same dose.
Phase 3 restructured this. It standardised on a 2 mg start, added a 6 mg intermediate step that did not exist in Phase 2, and moved the maintenance arms to 4, 9, and 12 mg. The 8 mg arm disappeared; 9 mg replaced it.
Pages quoting an 8 mg step are describing Phase 2. Pages quoting 9 mg are describing Phase 3. Pages quoting both in one ladder are describing neither.
What Each Maintenance Dose Actually Produced
This is the comparison that matters, and it is rarely presented in one place: what each dose bought in weight loss, and what it cost in tolerability.
| 4 mg | 9 mg | 12 mg | Placebo | |
|---|---|---|---|---|
| Weight loss at 80 weeks | 19.0% | 25.9% | 28.3% | 2.2% |
| Reached ≥30% loss | 15.3% | 37.9% | 45.3% | 0.5% |
| Discontinued (adverse events) | 4.1% | 6.9% | 11.3% | 4.9% |
| Dysesthesia (TRIUMPH-4) | — | 8.8% | 20.9% | 0.7% |
| Nausea | 28.6% | 38.4% | 42.4% | 14.8% |
Three things stand out. Complete efficacy results including responder rates break each dose down further.
4 mg is the sleeper result. It required a single escalation step, produced 19.0% weight loss — better than semaglutide’s pivotal trial result — and had a discontinuation rate of 4.1%, marginally below placebo. No other dose in the programme has that profile.
9 mg looks like the efficacy-tolerability midpoint. It captures 25.9% of the 28.3% available at 12 mg — roughly 92% of the effect — while dysesthesia runs at 8.8% instead of 20.9% and discontinuation at 6.9% instead of 11.3%.
12 mg has diminishing returns. Moving from 9 mg to 12 mg adds 2.4 percentage points of weight loss. It also roughly doubles the dysesthesia rate and increases discontinuation by more than half. See the full tolerability data by dose.
Is the Top Dose Worth It?
The dose-response curve is real but it flattens. Going from 4 mg to 9 mg adds 6.9 percentage points of weight loss. Going from 9 mg to 12 mg adds 2.4. The side-effect curve does the opposite — it steepens.
Weight loss rises and then flattens; discontinuation rises and then steepens
Source: Eli Lilly TRIUMPH-1, ADA 86th Scientific Sessions, June 2026. Dysesthesia figures from TRIUMPH-4, December 2025. Trial observations only — retatrutide has no approved dosage.
What the FDA makes of that pattern will shape the eventual label. Regulators weigh the benefit-risk ratio at each dose, and a dose that adds modest efficacy while roughly doubling a distinctive adverse event is exactly the kind of thing that draws scrutiny during review. It is entirely possible that an approved retatrutide looks different from the trial ceiling — a lower maximum, a slower titration, or dose-specific guidance based on tolerability.
That decision has not been made. No application has been filed.
How Retatrutide Titration Compares
| Retatrutide | Tirzepatide | Semaglutide | |
|---|---|---|---|
| Starting dose | 2 mg (trial) | 2.5 mg | 0.25 mg |
| Maximum studied/approved | 12 mg (trial) | 15 mg | 2.4 mg |
| Escalation interval | 4 weeks | 4 weeks | 4 weeks |
| Time to top dose | ~17 weeks | ~20 weeks | ~16 weeks |
| Approved dosing exists | No | Yes | Yes |
Milligram figures are not comparable across these drugs — they are different molecules with different potencies, so 12 mg of retatrutide is not “less” than 15 mg of tirzepatide in any meaningful sense. What is comparable is the structure: all three use four-week stepwise escalation for the same reason, which is that gastrointestinal tolerability is the limiting factor in this entire drug class. For the wider picture, see how the two drugs compare overall.
Why There Is No Approved Retatrutide Dosage
Everything above describes what researchers administered to screened, monitored participants under a controlled protocol. It is not prescribing information, and the distinction is not a formality.
An approved dosage carries things a trial protocol does not: a label reviewed by regulators, contraindications, interaction warnings, guidance for renal or hepatic impairment, adjustments for specific populations, and instructions for what to do when something goes wrong. None of that exists for retatrutide, because the FDA has not reviewed it — why no clinician can prescribe it yet sets out the legal position. Eli Lilly has said it will file a Biologics License Application in Q1 2027.
Trial participants also received dose holds and reductions from clinicians monitoring them. The schedule above is the plan; individual participants deviated from it under supervision.
For trial results, safety data, and the current regulatory position, browse all retatrutide research in one place.
Frequently Asked Questions
What is the standard retatrutide dosage?
There isn’t one. No approved dosage exists. In Phase 3 trials, maintenance arms were 4 mg, 9 mg, and 12 mg once weekly, reached by four-week stepwise escalation from a 2 mg start.
What is the maximum retatrutide dose?
12 mg once weekly is the highest dose studied in Phase 3. Whether that becomes the approved maximum is a decision for FDA review.
How long does it take to reach the full dose?
Around 17 weeks in the Phase 3 protocol — four weeks each at 2, 4, 6, and 9 mg before reaching 12 mg from week 17.
Which dose has the best balance of results and side effects?
On trial data, 9 mg captures roughly 92% of the weight loss available at 12 mg while dysesthesia runs at 8.8% versus 20.9% and discontinuation at 6.9% versus 11.3%. The 4 mg dose had the best tolerability of all, below placebo, at 19.0% weight loss.
Why do dosage charts online disagree?
Because Phase 2 and Phase 3 used different schedules. Phase 2 tested 1, 4, 8, and 12 mg with multiple escalation paths; Phase 3 standardised on a 2 mg start with a 6 mg intermediate step and maintenance arms at 4, 9, and 12 mg. Charts showing an 8 mg step are describing the older trial.
Is retatrutide taken daily or weekly?
Once weekly by subcutaneous injection in every trial, on a fixed seven-day interval.
Is there a retatrutide dosage chart?
The table and diagram above are the Phase 3 dosing schedule as published in the trial protocols: 2 mg for weeks 1–4, 4 mg for 5–8, 6 mg for 9–12, 9 mg for 13–16, then 12 mg from week 17. Charts elsewhere showing an 8 mg step are reproducing the older Phase 2 design.
Was 5 mg or 10 mg ever a retatrutide dose?
No. Phase 3 maintenance arms were 4 mg, 9 mg, and 12 mg, reached through 2 mg and 6 mg escalation steps. Phase 2 tested 1, 4, 8, and 12 mg. Neither 5 mg nor 10 mg was studied at any stage — those figures come from vendor vial and pen sizing, not from the trial programme — why vial and pen sizes don’t match any studied dose.
Is there a retatrutide dosing calculator?
No calculator can produce a valid dose for a drug with no approved dosing, no established contraindications, and no reviewed label. The trial schedule above is the complete published record of what was administered, under medical supervision, to screened participants.
Can a doctor prescribe a retatrutide dose?
No. Retatrutide is not approved, so no clinician can lawfully prescribe it and no pharmacy can dispense it. The only supervised access is clinical trial enrolment.
Sources
- Jastreboff AM, Kaplan LM, Frías JP, et al. “Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial.” N Engl J Med. 2023;389:514–526.
- Eli Lilly. TRIUMPH-1 topline results, May 21 2026; full data presented ADA 86th Scientific Sessions, June 6 2026.
- Eli Lilly. TRIUMPH-4 topline results, December 2025.
- Giblin K, Kaplan LM, Somers VK, et al. “Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials.” Diabetes Obes Metab. 2026;28(1):83–93.
- ClinicalTrials.gov: TRIUMPH-1 (NCT05929066), TRIUMPH-4.